- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07438041
Lier les jeunes aux services de prophylaxie pré-exposition (PrEP) (LYPS)
Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services (LYPS) : Une intervention innovante de distribution mobile et de santé mobile (mHealth) pour optimiser l'observance et la persistance à la PrEP
The LYPS intervention is a multi-level intervention that combines: a) structural-level delivery of PrEP and PrEP services by a community health professional (CHP) at a designated place in the community being offered by the SC where PrEP is not yet provided (e.g., participant's home, community partner location, or traveling mobile van), with b) an individual-level mobile application (app) to support PrEP adherence and persistence between CHP visits.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
LYPS is a two-arm randomized controlled trial (RCT) to assess the efficacy of the LYPS intervention. Up to 272 participants will be randomized in a 1:1 ratio to receive either the LYPS intervention or enhanced standard of care (eSOC) (136 participants per arm). The eSOC control condition will consist of usual clinic-based PrEP care and access to a limited number of LYPS app components. Participants will complete four research assessments, at Enrollment and Weeks 12, 24, and 36, that include computer-assisted self-interviews (CASIs) and blood collection. CASIs will collect information including, but not limited to, demographics, PrEP adherence and persistence, PrEP clinic visit attendance, PrEP knowledge and attitudes, PrEP self-efficacy, PrEP stigma, and psychosocial variables, questions that evaluate components of the LYPS intervention, tailored for intervention and eSOC conditions. Blood (dried blood spot [DBS] and plasma) will be collected to evaluate PrEP drug concentrations and stored for additional study-related testing.
All participants will receive daily oral PrEP, oral PrEP taken using a 2-1-1 dosing strategy, or injectable PrEP based on their preference and in consultation with their PrEP provider. There is no randomization involved for PrEP provision and participants are allowed to switch between oral and injectable PrEP or vice versa during the study. PrEP care visits (quarterly for those on oral PrEP and two monthly injections followed by an injection every two months for those on injectable PrEP) will include clinical labs such as HIV and STI testing and focused physical exams for signs and symptoms of HIV infection. Other relevant clinical data collected as part of the participant's PrEP clinical care will also be collected.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Nancy Liu
- Numéro de téléphone: 718-980-3937
- E-mail: NancyLiu@westat.com
Sauvegarde des contacts de l'étude
- Nom: Erin Ricketts
- Numéro de téléphone: 240-453-2786
- E-mail: ErinRicketts@westat.com
Lieux d'étude
-
-
California
-
San Francisco, California, États-Unis, 94102
- Recrutement
- San Francisco Department of Public Health
-
Chercheur principal:
- Albert Liu
-
Contact:
- Emily Schaeffer
- Numéro de téléphone: 628-217-7456
- E-mail: emily.schaeffer@sfdph.org
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- Emory Atlanta Adolescent Consortium
-
Chercheur principal:
- Andres Camacho-Gonzalez
-
Contact:
- Kaylin Dance
- Numéro de téléphone: (404) 727-5642
- E-mail: kaylin.dance@emory.edu
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Recrutement
- Johns Hopkins University
-
Contact:
- Jessica Coleman
- Numéro de téléphone: 301-385-4868
- E-mail: jcolem52@jh.edu
-
Chercheur principal:
- Allison Agwu
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- Baylor College of Medicine
-
Contact:
- Litty Koshy
- Numéro de téléphone: 832-822-1038
- E-mail: Litty.Koshy@bcm.edu
-
Chercheur principal:
- Mary Paul
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 13-24 years, inclusive;
- Reports anal or vaginal sex in the past year;
- Is not living with HIV;
- Weighs at least 35 kilograms (77 pounds);
- Willing to receive PrEP care from a provider at a participating SC either in the clinic or at one of the designated places in the community being offered by the SC SC;
- Has an Android-based smartphone or iPhone;
- Has fluency in English (able to read, speak, and understand English); and
- Willing to provide informed consent to participate in the study.
Exclusion Criteria:
- Has counter-indications for PrEP according to guidelines and approved local label;
- Has any clinically significant systemic disease (including but not limited to significant or uncontrolled liver disease, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis, or bone disease) or diabetes;
- Any other medical, behavioral, or other conditions that, in the opinion of the SC project lead or designee, could interfere with adherence to study procedures or compromise interpretation of study results;
- Concurrent participation in ATN 166, ATN 170, or any other clinical trial providing HIV medications (PrEP, vaccine, etc.) or currently receiving any PrEP-adherence or persistence behavioral intervention; or
- Is currently incarcerated or pending incarceration.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: LYPS Intervention
PrEP and PrEP care will be delivered to youth in the communities where they live through a Community Health Professional (CHP) (e.g., a nurse or other qualified health care professional home, friend's home, community venue or clinic, mobile health clinic), supplemented by a mobile app to provide real-time intervention between CHP visits. |
The LYPS intervention combines the use of a CHP to deliver PrEP services at a designated place in the community being offered by the SC where PrEP is not yet provided (e.g., participant's home, community partner location, or traveling mobile van) with an android-based smartphone or iphone app to support PrEP use between CHP visits. |
|
Comparateur actif: Enhanced Standard of Care (eSOC) Control Condition
Usual standard of care clinic-based PrEP, enhanced with access to a limited number of LYPS app components, including basic PrEP adherence information and study visit reminders. |
Clinic-based PrEP services per usual standard of care (e.g., HIV and STI testing, clinical assessments for signs and symptoms of HIV and PrEP safety) with access to a limited number of LYPS app components, including basic PrEP adherence information and study visit reminders. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
PrEP adherence at 6 months
Délai: 6 months
|
Determine adherence outcomes as measured by blood will be tailored for oral PrEP modality (daily oral or 2-1-1) and target vs. non-target PrEP concentration thresholds (depending on regimen) will be examined. Adherence outcomes for participants on injectable PrEP will be determined by the timely (± 1 week for the second injection; ± 2 weeks for any subsequent injection) administration of injections. |
6 months
|
|
PrEP persistence at 6 months
Délai: 6 months
|
Access persistence measures as based on 1) participant's self-report of currently taking PrEP (daily or 2-1-1) or having received last shot of injectable PrEP, and 2) has an active prescription for PrEP based on study records or drug level associated with use at 6 months. |
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
PrEP adherence at 9 months
Délai: 9 months
|
Determine adherence outcomes as measured by blood will be tailored for oral PrEP modality (daily oral or 2-1-1) and target vs. non-target PrEP concentration thresholds (depending on regimen) will be examined. Adherence outcomes for participants on injectable PrEP will be determined by the timely (± 1 week for the second injection; ± 2 weeks for any subsequent injection) administration of injections. |
9 months
|
|
PrEP persistence at 9 months
Délai: 9 months
|
Access persistence measures as based on 1) participant's self-report of currently taking PrEP (daily or 2-1-1) or having received last shot of injectable PrEP, and 2) has an active prescription for PrEP based on study records or drug level associated with use at 9 months. |
9 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Lisa Hightow-Weidman, MD, MPH, Florida State University
- Chaise d'étude: Kate Muessig, Florida State University
- Chaise d'étude: Keith Horvath, San Diego State University
- Chaise d'étude: Audrey Pettifor, UNC Chapel Hill
- Chercheur principal: Sybil Hosek, PhD, University of Illinois Chicago
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- ATN165
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .